NYSE$AGL
agilon health inc. · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
agilon health's Q1 2023 earnings were reported, showcasing revenue growth and increased Medicare Advantage membership.
agilon health reported a strong first quarter in 2023, with a 74% increase in revenue to $1.14 billion and a 61% increase in Medicare Advantage membership to 402,200. The company's net income rose to $16 million, and gross profit increased to $77 million.
- Total members on the agilon platform increased to 490,900, including 402,200 Medicare Advantage members and 88,700 ACO REACH beneficiaries.
- Total revenue increased by 74% to $1.14 billion compared to $653 million in the first quarter of 2022.
- Medical Margin increased by 88% to $162 million, representing 14.3% of revenue.
- Adjusted EBITDA was $24 million, including $12 million in geography entry costs.
Headline financials
Revenue & EPS history
agilon health · Revenue · Quarterly
$1.14B
Revenue by segment
agilon health · $1.14B total across 2 segments · Q1 2023
- Medical Services Revenue$1.13B+73.9%99.9%
- Other Operating Revenue$1.32M+28.9%0.1%
Forward guidance
agilon health provided guidance for the second quarter and fiscal year 2023, including expectations for Medicare Advantage members, ACO REACH members, total members, total revenues, medical margin, and Adjusted EBITDA.
Tailwinds
- Medicare Advantage Members: Expect between 403,000 and 405,000 for Q2 2023, and between 405,000 and 410,000 for FY 2023.
- ACO REACH Members: Expect between 85,000 and 90,000 for both Q2 and FY 2023.
- Total Members Live on Platform: Expect between 488,000 and 495,000 for Q2 2023, and between 490,000 and 500,000 for FY 2023.
- Total Revenues: Expect between $1,105 million and $1,115 million for Q2 2023, and between $4,410 million and $4,440 million for FY 2023.
- Adjusted EBITDA contribution from ACO REACH is expected in a range of $5 million to $10 million for 2023.
Headwinds
- Medical Margin: Expect between $138 million and $148 million for Q2 2023, and between $535 million and $560 million for FY 2023.
- Adjusted EBITDA: Expect between $2 million and $10 million for Q2 2023, and between -$3 million and $25 million for FY 2023.
- Geography Entry Costs: Expect between $19 million and $16 million for Q2 2023, and between $78 million and $65 million for FY 2023.
- Guidance for Medical Margin to Gross Profit or Adjusted EBITDA to net income (loss) not reconciled.
- Forward-looking guidance for net income (loss) not provided.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-2.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+6.7%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+20.2%
Q4 2025
Best reaction
-36.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +122.0% | +256.9% | |
| Q4 2025 | +20.2% | +13.4% | -20.8% | |
| Q3 2025 | +5.1% | -9.0% | -9.9% | |
| Q1 2025 | -25.6% | -33.4% | -51.6% | |
| Q4 2024 | -7.4% | -17.9% | +23.7% | |
| Q3 2024 | -36.1% | -35.1% | -24.7% | |
| Q2 2024 | -12.7% | -14.6% | -36.8% | |
| Q1 2024 | +7.5% | +7.5% | +40.8% | |
| Q4 2023 | +3.1% | -2.1% | -1.1% | |
| Q3 2023 | -13.1% | -19.0% | -33.1% | |
| Q2 2023 | +0.7% | +3.7% | -7.9% | |
| Q1 2023 | -3.4% | -6.6% | -18.9% | |
| Q4 2022 | +15.4% | +14.8% | +12.0% | |
| Q3 2022 | -12.7% | -7.9% | -8.6% | |
| Q2 2022 | -3.3% | -0.4% | -20.3% | |
| Q1 2022 | -8.6% | -19.4% | +1.3% | |
| Q4 2021 | +10.6% | +2.4% | +31.7% | |
| Q3 2021 | +2.7% | +3.6% | -9.5% | |
| Q2 2021 | -3.8% | -6.3% | -3.4% | |
| Q1 2021 | +6.3% | +4.0% | +14.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro